Published in Chemistry on June 16, 2003
Noninvasive visualization of the activated alphavbeta3 integrin in cancer patients by positron emission tomography and [18F]Galacto-RGD. PLoS Med (2005) 3.12
18F-labeled galacto and PEGylated RGD dimers for PET imaging of αvβ3 integrin expression. Mol Imaging Biol (2009) 1.90
Radiolabeled cyclic RGD peptides as integrin alpha(v)beta(3)-targeted radiotracers: maximizing binding affinity via bivalency. Bioconjug Chem (2009) 1.88
Design, synthesis, and evaluation of near infrared fluorescent multimeric RGD peptides for targeting tumors. J Med Chem (2006) 1.71
Improved targeting of the alpha(v)beta (3) integrin by multimerisation of RGD peptides. Eur J Nucl Med Mol Imaging (2006) 1.66
18F-labeled mini-PEG spacered RGD dimer (18F-FPRGD2): synthesis and microPET imaging of alphavbeta3 integrin expression. Eur J Nucl Med Mol Imaging (2007) 1.49
microPET of tumor integrin alphavbeta3 expression using 18F-labeled PEGylated tetrameric RGD peptide (18F-FPRGD4). J Nucl Med (2007) 1.46
Improving tumor-targeting capability and pharmacokinetics of (99m)Tc-labeled cyclic RGD dimers with PEG(4) linkers. Mol Pharm (2009) 1.41
Alphavbeta3-integrin imaging: a new approach to characterise angiogenesis? Eur J Nucl Med Mol Imaging (2006) 1.39
Improving tumor uptake and pharmacokinetics of (64)Cu-labeled cyclic RGD peptide dimers with Gly(3) and PEG(4) linkers. Bioconjug Chem (2009) 1.36
Launching a novel preclinical infrastructure: comparative oncology trials consortium directed therapeutic targeting of TNFalpha to cancer vasculature. PLoS One (2009) 1.33
Radiolabeled Cyclic RGD Peptides as Radiotracers for Imaging Tumors and Thrombosis by SPECT. Theranostics (2011) 1.25
Improving tumor uptake and excretion kinetics of 99mTc-labeled cyclic arginine-glycine-aspartic (RGD) dimers with triglycine linkers. J Med Chem (2008) 1.18
Positron emission tomography tracers for imaging angiogenesis. Eur J Nucl Med Mol Imaging (2010) 1.15
Role of phosphatidylserine receptors in enveloped virus infection. J Virol (2014) 1.10
Multivalent scaffolds for affinity maturation of small molecule cell surface binders and their application to prostate tumor targeting. J Med Chem (2009) 1.10
Advantages of RGD peptides for directing cell association with biomaterials. Biomaterials (2011) 1.06
Programmable multivalent display of receptor ligands using peptide nucleic acid nanoscaffolds. Nat Commun (2012) 1.06
Paramagnetic and fluorescent liposomes for target-specific imaging and therapy of tumor angiogenesis. Angiogenesis (2010) 1.05
Imaging key biomarkers of tumor angiogenesis. Theranostics (2012) 1.03
Clinical Application of Radiolabeled RGD Peptides for PET Imaging of Integrin αvβ3. Theranostics (2016) 1.02
2-Mercaptoacetylglycylglycyl (MAG2) as a bifunctional chelator for 99mTc-labeling of cyclic RGD dimers: effect of technetium chelate on tumor uptake and pharmacokinetics. Bioconjug Chem (2009) 1.01
Impact of PKM linkers on biodistribution characteristics of the 99mTc-labeled cyclic RGDfK dimer. Bioconjug Chem (2006) 1.00
Linker effects on biological properties of 111In-labeled DTPA conjugates of a cyclic RGDfK dimer. Bioconjug Chem (2007) 1.00
PET imaging of αvβ₃ integrin expression in tumours with ⁶⁸Ga-labelled mono-, di- and tetrameric RGD peptides. Eur J Nucl Med Mol Imaging (2010) 1.00
Design, synthesis, and validation of a branched flexible linker for bioactive peptides. J Org Chem (2007) 0.98
99mTcO(MAG2-3G3-dimer): a new integrin alpha(v)beta(3)-targeted SPECT radiotracer with high tumor uptake and favorable pharmacokinetics. Eur J Nucl Med Mol Imaging (2009) 0.97
In vivo imaging of tumour angiogenesis in mice with the alpha(v)beta (3) integrin-targeted tracer 99mTc-RAFT-RGD. Eur J Nucl Med Mol Imaging (2007) 0.96
Development and evaluation of peptidic ligands targeting tumour-associated urokinase plasminogen activator receptor (uPAR) for use in alpha-emitter therapy for disseminated ovarian cancer. Eur J Nucl Med Mol Imaging (2007) 0.96
Evaluation of In-Labeled Cyclic RGD Peptides: Effects of Peptide and Linker Multiplicity on Their Tumor Uptake, Excretion Kinetics and Metabolic Stability. Theranostics (2011) 0.95
Comparison of cyclic RGD peptides for αvβ3 integrin detection in a rat model of myocardial infarction. EJNMMI Res (2013) 0.94
Coligand effects on the solution stability, biodistribution and metabolism of the (99m)Tc-labeled cyclic RGDfK tetramer. Nucl Med Biol (2007) 0.94
PET Imaging of Angiogenesis. PET Clin (2009) 0.94
Evaluation of 111In-labeled cyclic RGD peptides: tetrameric not tetravalent. Bioconjug Chem (2010) 0.92
Application of a trifunctional reactive linker for the construction of antibody-drug hybrid conjugates. Bioorg Med Chem Lett (2008) 0.90
Redirecting lentiviral vectors by insertion of integrin-tageting peptides into envelope proteins. J Gene Med (2009) 0.89
Multivalent bifunctional chelator scaffolds for gallium-68 based positron emission tomography imaging probe design: signal amplification via multivalency. Bioconjug Chem (2011) 0.88
Interface Immobilization Chemistry of cRGD-based Peptides Regulates Integrin Mediated Cell Adhesion. Adv Funct Mater (2013) 0.88
One-step and one-pot-two-step radiosynthesis of cyclo-RGD-(18)F-aryltrifluoroborate conjugates for functional imaging. Am J Nucl Med Mol Imaging (2013) 0.87
Efficient method for site-specific 18F-labeling of biomolecules using the rapid condensation reaction between 2-cyanobenzothiazole and cysteine. Bioconjug Chem (2012) 0.87
Regiospecific syntheses of functionalized diaryliodonium tosylates via [hydroxy(tosyloxy)iodo]arenes generated in situ from (diacetoxyiodo)arenes. J Org Chem (2012) 0.87
Tumor-targeted in vivo gene silencing via systemic delivery of cRGD-conjugated siRNA. Nucleic Acids Res (2014) 0.85
Preclinical molecular imaging of tumor angiogenesis. Q J Nucl Med Mol Imaging (2010) 0.83
A chemically cross-linked knottin dimer binds integrins with picomolar affinity and inhibits tumor cell migration and proliferation. J Am Chem Soc (2014) 0.82
Application of click-click chemistry to the synthesis of new multivalent RGD conjugates. Org Biomol Chem (2010) 0.81
Rigid multivalent scaffolds based on adamantane. J Org Chem (2008) 0.80
Impact of multiple negative charges on blood clearance and biodistribution characteristics of 99mTc-labeled dimeric cyclic RGD peptides. Bioconjug Chem (2014) 0.80
Solid-phase synthesis of tailed cyclic RGD peptides using glutamic acid: unexpected glutarimide formation. J Pept Sci (2008) 0.78
In vivo biokinetic and metabolic characterization of the (68)Ga-labelled α5β1-selective peptidomimetic FR366. Eur J Nucl Med Mol Imaging (2015) 0.77
A molecular smart surface for spatio-temporal studies of cell mobility. PLoS One (2015) 0.75
Stroma targeting nuclear imaging and radiopharmaceuticals. Int J Mol Imaging (2012) 0.75
Self/co-assembling peptide, EAR8-II, as a potential carrier for a hydrophobic anticancer drug pirarubicin (THP)--characterization and in-vitro delivery. Int J Mol Sci (2013) 0.75
Crystal structure of the extracellular segment of integrin alpha Vbeta3 in complex with an Arg-Gly-Asp ligand. Science (2002) 7.87
RGD modified polymers: biomaterials for stimulated cell adhesion and beyond. Biomaterials (2003) 5.34
Activation of integrin function by nanopatterned adhesive interfaces. Chemphyschem (2004) 4.66
Cell spreading and focal adhesion dynamics are regulated by spacing of integrin ligands. Biophys J (2007) 3.57
Noninvasive visualization of the activated alphavbeta3 integrin in cancer patients by positron emission tomography and [18F]Galacto-RGD. PLoS Med (2005) 3.12
Structure and mechanics of integrin-based cell adhesion. Curr Opin Cell Biol (2007) 2.48
[18F]Galacto-RGD: synthesis, radiolabeling, metabolic stability, and radiation dose estimates. Bioconjug Chem (2004) 2.20
Two-step methodology for high-yield routine radiohalogenation of peptides: (18)F-labeled RGD and octreotide analogs. J Nucl Med (2004) 2.14
N-methylation of peptides: a new perspective in medicinal chemistry. Acc Chem Res (2008) 2.02
Three-dimensional EM structure of the ectodomain of integrin {alpha}V{beta}3 in a complex with fibronectin. J Cell Biol (2005) 1.97
Positron emission tomography using [18F]Galacto-RGD identifies the level of integrin alpha(v)beta3 expression in man. Clin Cancer Res (2006) 1.96
Perspectives on NMR in drug discovery: a technique comes of age. Nat Rev Drug Discov (2008) 1.95
WT p53, but not tumor-derived mutants, bind to Bcl2 via the DNA binding domain and induce mitochondrial permeabilization. J Biol Chem (2006) 1.94
Lateral spacing of integrin ligands influences cell spreading and focal adhesion assembly. Eur J Cell Biol (2005) 1.93
An unfolded CH1 domain controls the assembly and secretion of IgG antibodies. Mol Cell (2009) 1.90
Cilengitide: the first anti-angiogenic small molecule drug candidate design, synthesis and clinical evaluation. Anticancer Agents Med Chem (2010) 1.87
The RGD motif in fibronectin is essential for development but dispensable for fibril assembly. J Cell Biol (2007) 1.81
Impact of order and disorder in RGD nanopatterns on cell adhesion. Nano Lett (2009) 1.75
Inhibition of integrin alphavbeta6 on cholangiocytes blocks transforming growth factor-beta activation and retards biliary fibrosis progression. Gastroenterology (2008) 1.69
A novel adaptation of the integrin PSI domain revealed from its crystal structure. J Biol Chem (2004) 1.68
Crystal structure of the complete integrin alphaVbeta3 ectodomain plus an alpha/beta transmembrane fragment. J Cell Biol (2009) 1.68
Asymmetric activation of the hsp90 dimer by its cochaperone aha1. Mol Cell (2010) 1.65
A conserved spider silk domain acts as a molecular switch that controls fibre assembly. Nature (2010) 1.65
The N-terminal domain of p53 is natively unfolded. J Mol Biol (2003) 1.62
Ligands for mapping alphavbeta3-integrin expression in vivo. Acc Chem Res (2009) 1.60
Impact of local versus global ligand density on cellular adhesion. Nano Lett (2011) 1.58
Improving oral bioavailability of peptides by multiple N-methylation: somatostatin analogues. Angew Chem Int Ed Engl (2008) 1.48
alphav beta 3 and alphav beta 5 integrin antagonists inhibit angiogenesis in vitro. Angiogenesis (2003) 1.48
Carbohydrate-based mimetics in drug design: sugar amino acids and carbohydrate scaffolds. Chem Rev (2002) 1.46
New insights into the structural basis of integrin activation. Blood (2003) 1.45
Protein repellent properties of covalently attached PEG coatings on nanostructured SiO(2)-based interfaces. Biomaterials (2007) 1.44
Induction of cell polarization and migration by a gradient of nanoscale variations in adhesive ligand spacing. Nano Lett (2008) 1.43
PET Imaging of Integrin αVβ3 Expression. Theranostics (2011) 1.41
Pharmacological inhibition of integrin alphavbeta3 aggravates experimental liver fibrosis and suppresses hepatic angiogenesis. Hepatology (2009) 1.39
Radiation sensitization of glioblastoma by cilengitide has unanticipated schedule-dependency. Int J Cancer (2009) 1.39
Coming to grips with integrin binding to ligands. Curr Opin Cell Biol (2002) 1.38
The architecture of functional modules in the Hsp90 co-chaperone Sti1/Hop. EMBO J (2012) 1.36
Nanomolar small molecule inhibitors for alphav(beta)6, alphav(beta)5, and alphav(beta)3 integrins. J Med Chem (2002) 1.31
PET imaging of CXCR4 receptors in cancer by a new optimized ligand. ChemMedChem (2011) 1.28
Imaging of integrin alpha(v)beta(3) expression in patients with malignant glioma by [18F] Galacto-RGD positron emission tomography. Neuro Oncol (2009) 1.27
Hsp90 is regulated by a switch point in the C-terminal domain. EMBO Rep (2009) 1.24
Assessment of alphavbeta3 integrin expression after myocardial infarction by positron emission tomography. Cardiovasc Res (2008) 1.21
Multiple N-methylation of MT-II backbone amide bonds leads to melanocortin receptor subtype hMC1R selectivity: pharmacological and conformational studies. J Am Chem Soc (2010) 1.20
NMR chemical shift perturbation study of the N-terminal domain of Hsp90 upon binding of ADP, AMP-PNP, geldanamycin, and radicicol. Chembiochem (2003) 1.20
Cooperativity in adhesion cluster formation during initial cell adhesion. Biophys J (2008) 1.18
Optimized selective N-methylation of peptides on solid support. J Pept Sci (2006) 1.18
The structures of integrins and integrin-ligand complexes: implications for drug design and signal transduction. Angew Chem Int Ed Engl (2002) 1.17
First (18)F-labeled tracer suitable for routine clinical imaging of sst receptor-expressing tumors using positron emission tomography. Clin Cancer Res (2004) 1.15
CYR61 and alphaVbeta5 integrin cooperate to promote invasion and metastasis of tumors growing in preirradiated stroma. Cancer Res (2008) 1.15
Tumor Targeting via Integrin Ligands. Front Oncol (2013) 1.15
Hsp12 is an intrinsically unstructured stress protein that folds upon membrane association and modulates membrane function. Mol Cell (2010) 1.14
PET of CXCR4 expression by a (68)Ga-labeled highly specific targeted contrast agent. J Nucl Med (2011) 1.13
Intrinsic inhibition of the Hsp90 ATPase activity. J Biol Chem (2006) 1.13
BclxL changes conformation upon binding to wild-type but not mutant p53 DNA binding domain. J Biol Chem (2009) 1.12
The effect of multiple N-methylation on intestinal permeability of cyclic hexapeptides. Mol Pharm (2011) 1.10
Transmembrane signal transduction of the alpha(IIb)beta(3) integrin. Protein Sci (2002) 1.10
In support of the BMRB. Nat Struct Mol Biol (2012) 1.09
p53--a natural cancer killer: structural insights and therapeutic concepts. Angew Chem Int Ed Engl (2006) 1.08
Cellular unbinding forces of initial adhesion processes on nanopatterned surfaces probed with magnetic tweezers. Nano Lett (2006) 1.08
A computational model of transmembrane integrin clustering. Structure (2004) 1.08
Cilengitide inhibits progression of experimental breast cancer bone metastases as imaged noninvasively using VCT, MRI and DCE-MRI in a longitudinal in vivo study. Int J Cancer (2011) 1.07
Telethonin deficiency is associated with maladaptation to biomechanical stress in the mammalian heart. Circ Res (2011) 1.07
Convenient synthesis of N-methylamino acids compatible with Fmoc solid-phase peptide synthesis. J Org Chem (2005) 1.07
Structural analysis of the interaction between Hsp90 and the tumor suppressor protein p53. Nat Struct Mol Biol (2011) 1.05
Cell interactions with hierarchically structured nano-patterned adhesive surfaces. Soft Matter (2009) 1.05
Integrin control of the transforming growth factor-β pathway in glioblastoma. Brain (2013) 1.05
Synthesis and stereochemical assignment of DNA spore photoproduct analogues. Chemistry (2006) 1.04
Invasion patterns in brain metastases of solid cancers. Neuro Oncol (2013) 1.04
Synthesis of novel 1,4,7,10-tetraazacyclodecane-1,4,7,10-tetraacetic acid (DOTA) derivatives for chemoselective attachment to unprotected polyfunctionalized compounds. Chemistry (2007) 1.03
Photoswitched cell adhesion on surfaces with RGD peptides. J Am Chem Soc (2005) 1.03
Pharmacological inhibition of the vitronectin receptor abrogates PDGF-BB-induced hepatic stellate cell migration and activation in vitro. J Hepatol (2006) 1.03
N-methylation of peptides and proteins: an important element for modulating biological functions. Angew Chem Int Ed Engl (2012) 1.03
Mimicking cellular environments by nanostructured soft interfaces. Nano Lett (2007) 1.02
3-Substituted indolizine-1-carbonitrile derivatives as phosphatase inhibitors. Bioorg Med Chem Lett (2005) 1.02
Molecular targeting with peptides or peptide-polymer conjugates: just a question of size? J Nucl Med (2005) 1.02
Characterization of human saposins by NMR spectroscopy. Biochemistry (2006) 1.02
αv-Integrin isoform expression in primary human tumors and brain metastases. Int J Cancer (2013) 1.01
Ovarian cancer cell proliferation and motility is induced by engagement of integrin alpha(v)beta3/Vitronectin interaction. Biol Chem (2003) 1.01
N-methylated cyclic pentaalanine peptides as template structures. J Am Chem Soc (2006) 1.01
Dissecting the role of matrix metalloproteinases (MMP) and integrin alpha(v)beta3 in angiogenesis in vitro: absence of hemopexin C domain bioactivity, but membrane-Type 1-MMP and alpha(v)beta3 are critical. Cancer Res (2005) 1.00
Intestinal permeability of cyclic peptides: common key backbone motifs identified. J Am Chem Soc (2012) 1.00
Diffusion NMR spectroscopy: folding and aggregation of domains in p53. Chembiochem (2005) 1.00
FOSL1 controls the assembly of endothelial cells into capillary tubes by direct repression of αv and β3 integrin transcription. Mol Cell Biol (2013) 1.00
68Ga-NODAGA-RGD is a suitable substitute for (18)F-Galacto-RGD and can be produced with high specific activity in a cGMP/GRP compliant automated process. Nucl Med Biol (2012) 0.99
Design, synthesis, and functionalization of dimeric peptides targeting chemokine receptor CXCR4. J Med Chem (2011) 0.98
Circulating and imaging markers for angiogenesis. Angiogenesis (2008) 0.98
Solid-phase synthesis of 1,3-azole-based peptides and peptidomimetics. Org Lett (2006) 0.96
Design of selective peptidomimetic agonists for the human orphan receptor BRS-3. J Med Chem (2003) 0.96
Development and evaluation of peptidic ligands targeting tumour-associated urokinase plasminogen activator receptor (uPAR) for use in alpha-emitter therapy for disseminated ovarian cancer. Eur J Nucl Med Mol Imaging (2007) 0.96
Transcriptional regulation by antitermination. Interaction of RNA with NusB protein and NusB/NusE protein complex of Escherichia coli. J Mol Biol (2002) 0.96
Cooperative binding of p53 to DNA: regulation by protein-protein interactions through a double salt bridge. Angew Chem Int Ed Engl (2005) 0.96
The CLIP/CLAP-HSQC: pure absorptive spectra for the measurement of one-bond couplings. J Magn Reson (2008) 0.95
Evidence for hetero-association of transmembrane helices of integrins. FEBS Lett (2004) 0.95
Polymeric substrates with tunable elasticity and nanoscopically controlled biomolecule presentation. Langmuir (2010) 0.95
NMR studies on the substrate-binding domains of the thermosome: structural plasticity in the protrusion region. J Mol Biol (2004) 0.94
Comparison of cyclic RGD peptides for αvβ3 integrin detection in a rat model of myocardial infarction. EJNMMI Res (2013) 0.94
Design and chemical synthesis of integrin ligands. Methods Enzymol (2007) 0.94
Titanium implant materials with improved biocompatibility through coating with phosphonate-anchored cyclic RGD peptides. Chembiochem (2005) 0.94